Literature DB >> 19841185

Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus.

Aurelia Lartigue1, Natacha Colliou, Sébastien Calbo, Arnault François, Serge Jacquot, Christophe Arnoult, Francois Tron, Daniele Gilbert, Philippe Musette.   

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by pathogenic autoantibodies directed against nuclear Ags and immune complex deposits in damaged organs. Environmental factors have been thought to play a role in the onset of the disease. The recognition of these factors is mediated by TLRs, in particular TLR2 and TLR4 which bind pathogen-associated molecular patterns of Gram(+) and Gram(-) bacteria, respectively. We attempted to determine the role of these TLRs in SLE by creating TLR2- or TLR4-deficient C57BL/6(lpr/lpr) mice. These mice developed a less severe disease and fewer immunological alterations. Indeed, in C57BL/6(lpr/lpr)-TLR2 or -TLR4-deficient mice, glomerular IgG deposits and mesangial cell proliferation were dramatically decreased and antinuclear, anti-dsDNA, and anti-cardiolipin autoantibody titers were significantly reduced. However, the response against nucleosome remained unaffected, indicating a role of TLR2 and TLR4 in the production of Abs directed against only certain categories of SLE-related autoantigens. Analysis of B cell phenotype showed a significant reduction of marginal zone B cells, particularly in C57BL/6(lpr/lpr)-TLR4-deficient mice, suggesting an important role of TLR4 in the sustained activation of these cells likely involved in autoantibody production. Interestingly, the lack of TLR4 also affected the production of cytokines involved in the development of lupus disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19841185     DOI: 10.4049/jimmunol.0803219

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Glaucomatous tissue stress and the regulation of immune response through glial Toll-like receptor signaling.

Authors:  Cheng Luo; Xiangjun Yang; Angela D Kain; David W Powell; Markus H Kuehn; Gülgün Tezel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

2.  Toll-like receptor 4-activated B cells out-compete Toll-like receptor 9-activated B cells to establish peripheral immunological tolerance.

Authors:  Melanie P Matheu; Yan Su; Milton L Greenberg; Caroline A Blanc; Ian Parker; David W Scott; Michael D Cahalan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-17       Impact factor: 11.205

3.  B cell tolerance and positive selection in lupus.

Authors:  Dan Eilat; Matthias Wabl
Journal:  J Immunol       Date:  2012-07-15       Impact factor: 5.422

4.  Allelic variants in TLR10 gene may influence bilateral affectation and clinical course of Meniere's disease.

Authors:  Teresa Requena; Irene Gazquez; Antonia Moreno; Angel Batuecas; Ismael Aran; Andres Soto-Varela; Sofia Santos-Perez; Nicolas Perez; Herminio Perez-Garrigues; Alicia Lopez-Nevot; Eduardo Martin; Ricardo Sanz; Paz Perez; Gabriel Trinidad; Marta E Alarcon-Riquelme; Roberto Teggi; Laura Zagato; Miguel A Lopez-Nevot; Jose A Lopez-Escamez
Journal:  Immunogenetics       Date:  2013-02-01       Impact factor: 2.846

Review 5.  Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases.

Authors:  Jing Li; Xiaohui Wang; Fengchun Zhang; Hang Yin
Journal:  Pharmacol Ther       Date:  2013-03-24       Impact factor: 12.310

6.  A Link Between Plasma Microbial Translocation, Microbiome, and Autoantibody Development in First-Degree Relatives of Systemic Lupus Erythematosus Patients.

Authors:  Elizabeth Ogunrinde; Zejun Zhou; Zhenwu Luo; Alexander Alekseyenko; Quan-Zhen Li; Danielle Macedo; Diane L Kamen; Jim C Oates; Gary S Gilkeson; Wei Jiang
Journal:  Arthritis Rheumatol       Date:  2019-09-27       Impact factor: 10.995

7.  Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane.

Authors:  S A Summers; D Odobasic; M B Khouri; O M Steinmetz; Y Yang; S R Holdsworth; A R Kitching
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

8.  Lipopolysaccharide induces inducible nitric oxide synthase-dependent podocyte dysfunction via a hypoxia-inducible factor 1α and cell division control protein 42 and Ras-related C3 botulinum toxin substrate 1 pathway.

Authors:  Ahmad K Mashmoushi; Jim C Oates
Journal:  Free Radic Biol Med       Date:  2015-03-09       Impact factor: 7.376

Review 9.  Targeting Toll-like receptors for treatment of SLE.

Authors:  Christopher G Horton; Zi-jian Pan; A Darise Farris
Journal:  Mediators Inflamm       Date:  2010-09-19       Impact factor: 4.711

Review 10.  Toll-like receptor signaling pathways--therapeutic opportunities.

Authors:  Jiankun Zhu; Chandra Mohan
Journal:  Mediators Inflamm       Date:  2010-10-17       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.